Heads, Hearts, and Tails
Long-term compounding requires diligent work and staying power.
Distilled by 7Two (Dx72) is always searching our network for high-quality, growth-stage businesses, along with the occasional uncorrelated strategy.
We have 35 venture and growth sponsor relationships across 7Two.
7Two’s partners collectively review 200+ new funds/year, selectively adding to portfolios.
There are mini-monopolies constantly being created in new industries.
We approach growth investing with a patient discipline so that when the opportunity to buy arises, we’re ready to move quickly:
Spot them early. Do the work. Meet founders when possible. Get smart.
Invest at an inflection point - typically a Series B/C.
Own as much as you can as cheaply as possible.
Hold for as long as you can stand it.
Zipline is our poster child:
We underwrote our December 2025 SPV to a 4x at IPO in three years.
Secondary markets suggest we’ve already reached 2-3x on paper.
Hold it for a decade, and we think there is 50x potential. (Yes, Fifty.)*
Current themes and implications:
AI will accelerate robotics’ entry into the physical world. Be long deep tech.
Biotech makes nuclear winter look warm and cozy. For the survivors, this will probably be an above-average vintage.
Segments have become winner take all. Even the #2 company has a hard time capturing more than 20% marketshare.
As AI becomes ubiquitous, data will be the durable edge. The higher quality the data and more valuable to industry participants, the better.
Deflationary effects of software may be counteracted by cap-ex requirements and energy cost increases from massive data center infrastructure demand.
Upcoming Opportunities:
Secondary in a business currently raising a Series C led by a top five VC, growing at 8x for the past two years and estimated to triple in 2026.
Two soft-closed uncorrelated hedge funds where 7Two has distinct access.
Curious? Reach out. We’d love to start building trust and shared success.
*As with all deals, Zipline could still be a zero too.